Bo Xiong – Trademark Portfolio

Entity Type: 01

Bo Xiong holds 3 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 10 (Medical Apparatus) — 2 filings in this category. The portfolio also extends into Class 3 (Cosmetics & Cleaning) across 2 Nice Classification classes. Currently, 3 trademarks are registered. Notable registered marks include NEEIOTM, VISSTEAG, and BRYTYEFRY. The owner is based in Hubei Province.

Group 3, Dinghu Village,

Zhugentan Town, Qianjiang City,

Hubei Province 433100 , CN

3 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

VISSTEAG
VISSTEAG
Registered 2025
BRYTYEFRY
BRYTYEFRY
Registered 2025
NEEIOTM
NEEIOTM
Registered 2025

Trademark Classifications

Bo Xiong's trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.

10
Medical Apparatus (2 filings)

Surgical, medical, dental and veterinary apparatus and instruments

3
Cosmetics & Cleaning (1 filing)

Bleaching preparations and other substances for laundry use; cleaning, polishing, scouring

Frequently Asked Questions

How many trademarks does Bo Xiong have?

Bo Xiong has 3 U.S. trademarks filed with the USPTO. Of these, 3 registered.

What trademark classes does Bo Xiong file in?

Bo Xiong files trademarks across 2 Nice Classification classes. The most active classes are Class 10 (Medical Apparatus), Class 3 (Cosmetics & Cleaning). Class 10 covers surgical, medical, dental and veterinary apparatus and instruments.

What are Bo Xiong's most well-known trademarks?

Bo Xiong's registered trademark portfolio includes well-known marks such as NEEIOTM, VISSTEAG, and BRYTYEFRY. These are among 3 currently registered trademarks in the portfolio.

What is Bo Xiong's trademark registration success rate?

Bo Xiong has a 100% trademark registration rate, with 3 out of 3 resolved applications resulting in successful registration. Currently, 0 applications are pending review.